PHS
CYTR

Pekin Hardy Strauss’s CytRx Corp CYTR Stock Holding History

Pekin Hardy Strauss’s Portfolio CYTR Stock Details CYTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-16,261
Closed -$11K – 220
2019
Q1 		$11K Hold
16,261
– – ﹤0.01% 206
2018
Q4 		$7K Hold
16,261
– – ﹤0.01% 195
2018
Q3 		$17K Hold
16,261
– – ﹤0.01% 199
2018
Q2 		$18K Buy
16,261
+5,000
+44% +$7.47K ﹤0.01% 194
2018
Q1 		$18K Hold
11,261
– – ﹤0.01% 186
2017
Q4 		$19K Buy
11,261
+2
+0% +$4 ﹤0.01% 190
2017
Q3 		$28K Buy
11,259
+833
+8% +$2.81K 0.01% 189
2017
Q2 		$39K Buy
10,426
+4,408
+73% +$15.1K 0.01% 187
2017
Q1 		$16K Buy
6,018
+3,334
+124% +$8.44K ﹤0.01% 179
2016
Q4 		$6K Hold
2,684
– – ﹤0.01% 171
2016
Q3 		$9K Hold
2,684
– – ﹤0.01% 164
2016
Q2 		$36K Buy
2,684
+365
+16% +$6.07K 0.01% 163
2016
Q1 		$37K Buy
+2,319
New +$31.7K 0.01% 161

Other funds holding CYTR

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
CTA
Colonial Trust Advisors Spartanburg, South Carolina $1.44B AUM 26.89% 1-Year Est. Return

Pekin Hardy Strauss's CYTR Position: Q2 2019 in Review

Pekin Hardy Strauss sold out of CytRx Corp (CYTR) in Q2 2019, closing a stake of 16,261 shares — an estimated $11K sold.

Pekin Hardy Strauss first reported a position in CYTR in Q1 2016 and held it in 13 quarters. The position peaked at $39K in Q2 2017. 5 funds tracked by Wall St. Rank hold CYTR as of Q2 2019.

  • Pekin Hardy Strauss reported no remaining CytRx Corp position as of Q2 2019 after selling out during the quarter.
  • Pekin Hardy Strauss sold 16,261 CytRx Corp shares in Q2 2019, an estimated $11K.
  • Pekin Hardy Strauss first reported a position in CytRx Corp in Q1 2016 and held it in 13 quarters.
  • Pekin Hardy Strauss's CytRx Corp position peaked at $39K in Q2 2017.
  • 5 funds tracked by Wall St. Rank held CytRx Corp as of Q2 2019.

Based on Pekin Hardy Strauss's 13F filing for Q2 2019, filed 12 Aug 2019.